<bill session="117" type="h" number="6973" updated="2023-03-08T19:58:48Z">
  <state datetime="2022-03-08">REFERRED</state>
  <status>
    <introduced datetime="2022-03-08"/>
  </status>
  <introduced datetime="2022-03-08"/>
  <titles>
    <title type="display">Enhanced Access to Affordable Medicines Act of 2022</title>
    <title type="short" as="introduced">Enhanced Access to Affordable Medicines Act of 2022</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to clarify the conditions under which the Secretary of Health and Human Services can approve generic drug applications with labeling temporarily different than the brand name drug, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="C001103"/>
  <cosponsors>
    <cosponsor bioguide_id="C001119" joined="2022-04-26"/>
  </cosponsors>
  <actions>
    <action datetime="2022-03-08">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-03-08" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-03-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="4351" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-09-20T17:12:24Z" status="Introduced in House">Enhanced Access to Affordable Medicines Act of 2022

This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.</summary>
</bill>
